<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857437</url>
  </required_header>
  <id_info>
    <org_study_id>C4171001</org_study_id>
    <secondary_id>2020-002121-28</secondary_id>
    <nct_id>NCT04857437</nct_id>
  </id_info>
  <brief_title>Study in Healthy Adults Evaluating PF-07202954</brief_title>
  <official_title>A PHASE 1, 3-PART, SPONSOR OPEN STUDY OF PF-07202954 IN HEALTHY ADULTS: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE (IN PART 1), AND REPEATED (IN PART 2), ESCALATING, ORAL DOSES ALONG WITH CONDITIONAL PART 3 OF RANDOMIZED, OPEN-LABEL ASSESSMENT OF EFFECT OF FOOD ON PF-07202954 EXPOSURE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is planned as a 3 part design with investigator and participant blinded&#xD;
      (sponsor-open), placebo controlled, randomized, dose escalation in Part 1 and Part 2; and a&#xD;
      randomized, open label design, in Part 3 (if conducted).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 13, 2021</start_date>
  <completion_date type="Actual">September 17, 2021</completion_date>
  <primary_completion_date type="Actual">September 17, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects reporting treatment emergent adverse events (AEs)</measure>
    <time_frame>Baseline through follow up Day 30</time_frame>
    <description>Part 1 and Part 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment emergent clinical laboratory abnormalities</measure>
    <time_frame>Baseline through follow up Day 30</time_frame>
    <description>Part 1 and Part 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment emergent vital signs</measure>
    <time_frame>Baseline through follow up Day 30</time_frame>
    <description>Part 1 and Part 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment emergent Electrocardiogram (ECG) abnormalities</measure>
    <time_frame>Baseline through follow up Day 30</time_frame>
    <description>Part 1 and Part 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (C[max])</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 8, 12, 16 hour on Day 1, 24, 36 hour on Day 2, 48 hour on Day 3, 72 hour on Day 4</time_frame>
    <description>Part 3 (if conducted)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 8, 12, 16 hour on Day 1, 24, 36 hour on Day 2, 48 hour on Day 3, 72 hour on Day 4</time_frame>
    <description>Part 3 (if conducted)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time AUC[last])</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 8, 12, 16 hour on Day 1, 24, 36 hour on Day 2, 48 hour on Day 3, 72 hour on Day 4</time_frame>
    <description>Part 3 (if conducted)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve from Time Zero to Extrapolated Infinite Time (AUCinf)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 8, 12, 16 hour on Day 1, 24, 36 hour on Day 2, 48 hour on Day 3, 72 hour on Day 4</time_frame>
    <description>Part 3 (if conducted)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Part 1 - 0, 0.5, 1, 2, 3, 4, 5, 8, 12, 16 hour on Day 1, 24, 36 hour on Day 2, 48 hour on Day 3, 72 hour on Day 4. Part 2 (Single Dose) - Day 1. Part 2 (Repeat Dose) - Day 7 and Day 14</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Part 1 - 0, 0.5, 1, 2, 3, 4, 5, 8, 12, 16 hour on Day 1, 24, 36 hour on Day 2, 48 hour on Day 3, 72 hour on Day 4. Part 2 (Single Dose) - Day 1. Part 2 (Repeat Dose) - Day 7 and Day 14</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast</measure>
    <time_frame>Part 1 - 0, 0.5, 1, 2, 3, 4, 5, 8, 12, 16 hour on Day 1, 24, 36 hour on Day 2, 48 hour on Day 3, 72 hour on Day 4.</time_frame>
    <description>Part 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Part 1 - 0, 0.5, 1, 2, 3, 4, 5, 8, 12, 16 hour on Day 1, 24, 36 hour on Day 2, 48 hour on Day 3, 72 hour on Day 4.</time_frame>
    <description>Part 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)</measure>
    <time_frame>Part 2 (Single Dose) - Day 1. Part 2 (Repeat Dose) - Day 7 and Day 14</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time measured for plasma concentration to decrease by one half (Terminal half-life) [t(1/2)].</measure>
    <time_frame>Part 1 - 0, 0.5, 1, 2, 3, 4, 5, 8, 12, 16 hour on Day 1, 24, 36 hour on Day 2, 48 hour on Day 3, 72 hour on Day 4. Part 2 (Repeat Dose) - Day 14</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of unchanged drug recovered in urine during dosing interval (AE[tau])</measure>
    <time_frame>Day 14</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of dose recovered in urine as unchanged drug over dosing interval (AE[tau%])</measure>
    <time_frame>Day 14</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (CLr)</measure>
    <time_frame>Day 14</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs</measure>
    <time_frame>Baseline through follow up Day 30</time_frame>
    <description>Part 3 (if conducted)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent clinical laboratory abnormalities</measure>
    <time_frame>Baseline through follow up Day 30</time_frame>
    <description>Part 3 (if conducted)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent vital signs</measure>
    <time_frame>Baseline through follow up Day 30</time_frame>
    <description>Part 3 (if conducted)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG abnormalities</measure>
    <time_frame>Baseline through follow up Day 30</time_frame>
    <description>Part 3 (if conducted)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Liver Fibrosis</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, Escalating Doses of PF-07202954 or Placebo (Cohorts 1 and 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeated, Escalating Doses of PF-07202954 or placebo from Day 1 to Day 14, inclusive (Cohorts 3, 4, 5, 6 7, and optional Cohort 8)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of PF-07202954 with a high-fat/high-caloric meal and a single dose following an overnight fast of â‰¥10 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07202954 Repeat Dose</intervention_name>
    <description>10, 30, 100, 300, 600, 1200 milligrams (mg)</description>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07202954 Single Dose</intervention_name>
    <description>10, 30, 100, 300, 600, 900, 1200 milligrams (mg)</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:- healthy subjects (all 3 Parts)&#xD;
&#xD;
          -  evidence of steatosis on FibroScan (Part 2 only)&#xD;
&#xD;
          -  BMI 17.5 to 30.5 kg/m2 (Part 1, Part 3)&#xD;
&#xD;
          -  BMI 17.5 to 35.4 kg/m2 (Part 2) Exclusion Criteria:- evidence of clinically&#xD;
             significant disease&#xD;
&#xD;
          -  subjects on chronic medications&#xD;
&#xD;
          -  clinically significant, abnormal laboratory results, vital signs, or cardiac&#xD;
             conduction abnormalities&#xD;
&#xD;
          -  contraindication to MRI (Part 2, only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4171001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

